THE FUNCTION OF
… and Reduces
[For latest news, please scroll down! ]
Replicon Health is a Finnish development and commercialization company focusing on chronic diseases and in reducing low grade inflammation. Additionally, the mechanism of action of our very well tolerated molecule enhances the function of internal organs like the liver, the brain and the intestines. Simultaneous enhancement in local and systemic immune systems leads even to increased protection against viral and microbial infections. Our novel patented technology is based on several simultaneous enhancements of mitochondrial energy metabolism creating strong and sustained efficacy.
The innovation is based on reduced statistical modelling of ultra-complicated biological systems. With created low cost and high return strategy we have already been able to show in vivo efficacy in multiple tests with high statistical certainty. Our patented molecule formulation can uniquely influence the causes of many diseases and disorders, not just alleviate the symptoms.
Our total potential market is in excess of ten billion USD and feasible sales potential in selected markets is clearly above 500 million USD annually. We aim at relatively fast market entry with carefully selected medical solution. Importantly, also our proprietary mass production technology is environmentally sustainable.
19.10.2020 Scientific article related to human Breakthrough Therapy is ready for submission.
5.6.2020 Replicon’s RH013001 compound initiates 5-week LCR and HCR rat study with a 0-control and a positive control. Effect on aerobic capacity, body weigh and organs, and selected blood markers will be investigated.
9.4.2020 Replicon Health is temporarily fully committed in developing a drug that reduces the burden of hospital intensive care units due to viral pandemics like COVID-19. Substance has already been successfully tested in healthy humans. Targeted therapy covers the therapy area that we selected based on clinical trial 10-11/2019 but is much wider, now it covers all organs.
18.3.2020 Current pandemic crises causes an amendment to the side indications that Replicon will investigate in early clinical trials. Confidential selection of the main indication remains the same (see below). Long way to go but planning has been already started.
15.01.2020 Combining earlier human tissue data with received new data from living humans pave way for the selection of our focus Block Buster -indication with unmet medical need. Only now we possess adequate set of data and certainty for this crucial selection. Based on our several independent and verified human results RH013001 will extremely likely be able to address selected unmet medical need and enter the market in roughly 5-7 years from now. Benefit for the patients will be significant.
Global annual sales of the focus Block Buster -indication is some USD 10 bn, currently mostly off-label sales. It is expected to increase rapidly when new drugs get approvals. According to some market forecasts sales will soar to USD 40 billion by the year 2028. Our plan is to out-license first indication to some bigger pharma company after phase 2 tests.
08.01.2020 During early 2020 mRNA expressions at whole genome level will be analysed as well as certain pre-selected cytokines and other confirmatory markers. Already before these final analyses Replicon Health has gained enormously valuable clinical set of data from its patented therapeutic molecule. Benefits for the patients can be and cost savings for the health sector will be substantial.
12/2019 Supplementary results from the clinical trial confirm reduction of low-grade inflammation in apparently healthy older persons. Multiple shifts in energy metabolism enable surprisingly rapid adaptation of the immune system towards pathological and other threats.
11/2019 Preliminary results of the placebo controlled clinical study are very promising. Main therapeutic targets were reached, and the mechanism of action was re-confirmed.
09/2019 Recruiting of the study subjects has been completed. Experimental phase of the clinical study will start in October and last until November 2019.
07/2019 Major US patent granted for Replicon Health.
05/2019 Annual shareholder meeting on the 7th of May authorized two financing rounds. First, currently on-going share issue of up to 400 000 euro closes at the end of August 2019. The main share issue of up to 2-3 M€ for venture capitalist and other professionals will materialize later.
05/2019 Replicon receives an approval for a clinical study with healthy volunteers from Ethical Committee of a Central Hospital (KSSHP). Enhancement of aerobic energy metabolism and its positive effect towards inflammation in humans is the main interest of the study from Official Health Claim and commercialization point of view.
04/2019 Replicon Health Oy has filed its second commercialization application. This RH activator is targeted for human use with exceptionally strong sales potential. The unique selling proposal is the enhancement of overall aerobic energy metabolism and its strong, alleviating effect towards inflammation, e.g. flues and IBD.
02/2019 Experienced mitochondria researchers have obtained strong positive results on the efficacy of RH activators in enhancement of mitochondrial energy metabolism in whole organisms in their normal environment. Doses for the study were instructed by Replicon Health. These otherwise totally independent in vivo results have been verified by repetition of the test.
12/2018 New in vitro study on reactive oxygen species (ROS) by independent university researchers confirm that ROS scavenging by RH activators is more substantial towards mitochondrial ROS compared to cytosolic ROS. This is perfectly in line with the mechanism of action of RH activators.
10/2018 Replicon Health Oy has filed its first commercialization application. The proprietary new chemical entity can replace excessive use of antimicrobials. It has already been in limited commercial use in the EU area with successful outcomes.
09/2018 Confirmatory knowledge on health benefitting mitochondrial signalling revealed by GC-MS measurements.
08/2018 IPRs moving successfully in selected major market areas
07/2018 Replicon receives the major part of the R&D financing granted in 06/2017 by Business Finland (see below)
05/2018 Small bridge financing from current owners completed (at par value compared to previous round)
04/2018 Successful production related R&D project completed.
03/2018 Tissue / cell level protection against a specific viral infection shown in an in vitro study. (More influential / relevant systemic efficacy against viral infections indicated earlier in several in vivo studies.)
01/2018 New in vitro study confirms the activation of mitochondrial energy metabolism by RH activators in a new tissue type. The study was conducted by an independent university research group who used different analyzing technology compared to previous in vitro and in vivo studies with similar, fully consistent findings.
09/2017 Replicon Health moves to new bigger premises in Otaniemi, Espoo to facilitate smooth ramp up for commercialization of first prooducts.
06/2017 Replicon Health receives R&D financing from TEKES, Finnish Funding Agency for Innovation.
05/2017 Experimental challenge study with pathogenic gram-negative bacteria gave notably good and statistically very significant outcome compared to placebo. However, the experimental study set up had to be slightly modified during the study thus deteriorating scientific impact. Nevertheless, practical economic results were even better than expected.
03/2017 Confirmatory double controlled challenge study has reached its main end points. Conducted two latest efficacy studies now confirm that RH -activators can replace antimicrobial agents in practical applications. Both studies were conducted by independent experts and relevant efficacy results deviate statistically significantly from 0-control (placebo group) in both. Additionally, the test set-up was demanding in respect to revealing the efficacy of RH activators in both studies.
01/2017 Double controlled protozoal challenge study conducted in Oct – Nov 2016 has reached its primary end points. Additionally dose responses were consistent in the study thus confirming positive results. Second test has already been initiated.
10/2016 Replicon Health initiates a series of large scale efficacy studies for commercialization.
01/2016 Replicon Health has filed two additional patent applications related to its invention thus extending the already massive coverage of the IPRs and furthermore confirming the proof of concept of the main invention.